Abstract
The low water solubility of baricitinib (BCT) limits the development of new formulations for the topical delivery of the drug. The aims of this study were to assess the solubility of BCT in different solvents, including Transcutol, a biocompatible permeation enhancer that is miscible in water, to evaluate the drug uptake in human skin and porcine tissues (sclera, cornea, oral, sublingual, and vaginal), and to subsequently extract the drug from the tissues so as to determine the drug recovery using in vitro techniques. Analytical methods were developed and validated for the quantification of BCT in Transcutol using absorption and fluorescence spectroscopies, which are complementary to each other and permit the detection of the drug across a broad range of concentrations. Results show that Transcutol permits an increased drug solubility, and that BCT is able to penetrate the tissues studied. The solutions of BCT in Transcutol were stable for at least one week. Hence, Transcutol may be a suitable solvent for further development of topical formulations.
Reference66 articles.
1. Approaches for Breaking the Barriers of Drug Permeation through Transdermal Drug Delivery;Alexander;J. Control. Release,2012
2. Transmucosal Drug Administration as an Alternative Route in Palliative and End-of-Life Care during the COVID-19 Pandemic;Lam;Adv. Drug. Deliv. Rev.,2020
3. (2022, August 09). Drug Bank Baricitinib: Uses, Interactions, Mechanism of Action. Available online: https://go.drugbank.com/drugs/DB11817.
4. National Center for Biotechnology Information (2022, January 12). PubChem Database. PubChem Compound Summary for CID 44205240, Baricitinib, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Baricitinib.
5. Emerging Systemic JAK Inhibitors in the Treatment of Atopic Dermatitis: A Review of Abrocitinib, Baricitinib, and Upadacitinib;Nezamololama;Drugs Context,2020